These data suggest that reduced expression of AnxA6 and to some extent the relatively higher GRF2 expression levels are mostly associated with the more proliferative (higher Ki67 positivity) TNBC tumors, consistent with the reduced expression of AnxA6 in highly malignant cancers [16]. Here, RASGRF2 is linked to cancer.